Project Name：Cabazitaxel
Registration Classification：3.1
Formulations and specifications ：Injection 60mg/1.5ml (40mg/ml)
Indications：This product is applied to previous treatment of hormone refractory metastatic prostate cancer with prednisone combined with docetaxel -containing treatment regimen in patients with
Original Research Company：Sanofi-Aventis
Progress ：Pharmaceutical Research in progress
Category :Cancer drug
